“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

14 June 2019
Pharma

Visiongain has launched a new pharma report Generic Drugs Market Forecast: Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories Limited, Apotex.

Generic drugs play a major role in the pharmaceutical industry of most nations. This rings true for countries both in developed and developing economic regions. Generic drugs typically account for over 50-80% of pharmaceutical sales by volume and 10-20% of sales by value. Traditional pharmaceutical companies in the past have viewed generics as ways of diversifying their business. Over the last two decades, sales of these products in emerging markets in particular have provided major growth opportunities for traditional pharma companies.

The lead analyst of the report commented "Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area. At the same time, successful generic companies will try to innovate, pursuing more research-based pipeline candidates releasing patented drugs as well as high-value generics and biosimilars. A note of caution has to be sounded, however, in that we note that generic drug manufacturers must continuously revise their business models in an attempt to outsmart market challenges. New strategic decisions will have to be made to define their future path. This may include steps such as merging for scale, complementing the generic portfolio with a branded portfolio, or adding new offerings and services in order to provide new revenue streams."

Leading companies featured in the report include Abbott, Apotex, Aspen, Dr. Reddy’s Laboratories Limited, Fresenius Kabi, Mylan, Novartis, Pfizer, Sanofi, Sun Pharma, Teva and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Single-Cell Analysis Market Report 2022-2032

The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

26 May 2022

Read

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever